March 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb's BMY.N combination treatment for adults and adolescents aged 12 and older with previously untreated Stage III or IV classical Hodgkin's lymphoma.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.